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Abstract
Background: Allogeneic stem cell transplantation from haploidentical donor using an unmanipulated graft and
post-transplantation cyclophosphamide (PT-Cy) is growing. Haploidentical transplantation with PT-Cy showed a
major activity in Hodgkin lymphoma (HL), reducing the relapse incidence. The most important predictive factor of
survival and toxicity was disease status before transplantation, which was better in patients with well controlled
disease.
Methods: We included 198 HL in complete (CR) or partial remission (PR) before transplantation. Sixty-five patients
were transplanted from haploidentical donor and 133 from a HLA identical donor (both sibling and unrelated
donors). Survival analysis was defined according to the EBMT criteria. Survival curves were generated by using
Kaplan-Meier method and differences between groups were compared by the log rank test or by the log rank test
for trend when appropriated.
Results: The PFS, OS, and RI were significantly better in patients in CR compared to PR (55% vs 29% p = 0.001, 74%
vs 55% p = 0.03, 27% vs 55% p < 0.001, respectively). The 2-year PFS was significantly better for HAPLO than HLA-id
(63% vs 37%, p = 0.03), without difference in OS. The 1-year NRM was not different. The 2-year relapse incidence (RI)
was lower in the HAPLO group (24% vs 44%, p = 0.008). Patients in CR receiving haplo HSCT showed higher 2-year
PFS and lower 2-year RI than those allografted with HLA-id donor (75% vs 47%, p < 0.001 and 11% vs 34%, p <
0.001, respectively). In multivariate analysis, donor type and disease status before transplantation were independent
predictors of PFS as well as they predict the risk of relapse. Disease status at transplantation and age were
independently associated to OS.
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Conclusions: Nonetheless this is a retrospective study, limiting the wide applicability of results, data from this
analysis suggest that HLA mismatch can induce a strong graft versus lymphoma effect leading to an enhanced PFS.
Keywords: Haploidentical transplantation, Hodgkin lymphoma, Reduced intensity conditioning regimen
Background
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) represents a potential curative option for patients
with relapsed or refractory Hodgkin’s lymphoma (HL) [1–
5], and has shown to be offer a survival advantage, over
chemotherapy alone, for patients relapsing after an autolo-
gous transplant [4]. However, an HLA-identical related or
unrelated donor is available only for a subset of patients,
and family mismatched donors are warranted for such pa-
tients. The Baltimore group has shown that T cell-replete
haploidentical transplantation, is feasible following a non-
myeloablative conditioning regimen (NMAC) and post-
transplant cyclophosphamide (PT-Cy), with a good tox-
icity profile [6]. In a retrospective study on patients with
HL, the relapse risk was decreased in patients grafted from
a haploidentical (HAPLO) donor, compared patients
grafted from HLA identical sibling (SIBS) or unrelated do-
nors (UD), with a 2-year progression-free survival (PFS),
of 51% for HAPLO versus 23% for SIBS and 29% for UD
donors [7]. These results suggested a peculiar immuno-
logical graft-versus tumor effect of HAPLO donors against
HL cells [8–10].
Recently, lymphoma patients grafted with HAPLO do-
nors (using the Baltimore platform) was compared with
patients grafted with SIBS or matched unrelated donor
(MUD), in 3 registry based studies [11–13]. These stud-
ies showed comparable outcome, with a lower incidence
of chronic GVHD after HAPLO grafts. The EBMT
study, focusing on HL, also showed comparable out-
come, but included chemosensitive and chemorefractory
patients. We hypothesized that chemosensitive HL pa-
tients would be best suited to test whether HAPLO do-
nors would induce a stronger graft versus lymphoma
effect, as compared to SIBS and UD. We are now report-
ing a comparative analysis of 198 patients with HL with
chemosensitive disease receiving allo-HSCT from SIBS/
MUD, or HAPLO donor.
Methods
In this analysis we included HL patients receiving haplo-
HSCT, in 3 Centers (Humanitas Research Hospital, Roz-
zano; Ospedale San Martino, Genova; Institut Paoli
Calmettes, Marseille, France) and HL patients receiving,
during the same period (from 2009 to 2012), a HLA
identical transplantation, both from related or unrelated
donor, selected by centers from the Gruppo Italiano
Trapianto di Midollo e cellule staminali periferiche
(GITMO). This retrospective study was approved by eth-
ical committee (ONC/OSS 04/2015).
Search for allogeneic stem cell donor was initiated for
patients relapsing after high-dose chemotherapy or re-
quiring three or more chemotherapy lines to control ini-
tial disease, or in case of disease refractory to salvage
chemotherapy. For patients lacking an HLA-id sib or
UD, haploidentical donor was searched.
We analyzed if the survival was different between
HLAid and MUD, and the 2-year PFS and OS were not
statistically different (HLAid vs MUD, 2-y PFS 28 vs
38% (p 0.47); 2-y OS 73% vs 53% (p 0.087), allowing us
to combine them.
Inclusion criteria
We included only chemosensitive (complete remission, CR
or partial remission, PR) patients before allo-HSCT, per-
formed during the same time frame (from 2010 and 2014):
65 patients received haploidentical transplantation (Haplo-
HSCT) and 133 HLA-identical (HLA-id) transplantation,
both from sibling and unrelated donors. The institutional re-
view board of each center approved the study.
Haploidentical transplantation
Patients were conditioned using nonmyeloblative condi-
tioning regimen including Cy 14.5mg/kg on days − 5 and
− 6, fludarabine 30mg/m2 from day − 6 to day − 2 and
low-dose TBI (2 Gy) on day − 1. RIC regimen was used in
one patient associating consisting of thiotepa 10mg/kg,
fludarabine 30mg/m2, and cyclophosphamide 30mg/kg.
GVHD prophylaxis consisted of Cy 50mg/kg adminis-
tered on days + 3 and + 4. On day + 5, tacrolimus or cyclo-
sporine A (CyA) and mycophenolate mofetil (MMF) were
started. Tacrolimus (FK 506, at a total dose of 1mg) was
administered as a continuous infusion until discharge and
was converted to an oral formulation thereafter. The doses
were adjusted to obtain serum levels between 10 and 20
ng/ml. CyA was dosed at 3 mg/kg as a continuous infusion
until discharge and was converted to an oral formulation
thereafter. The CyA doses were modified to obtain serum
levels between 100 and 200 ng/ml. MMF was adminis-
tered at 15mg/kg po three times per day until day + 35.
G-CSF was started on day + 5 in all the patients.
HLA identical transplantation
We will consider together patients grafted from identical
siblings, and patients grafted from 8/8 matched
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unrelated donors, and we will refer to these as HLA
identical transplants. Several reduced conditioning regi-
mens were used for patients grafted from HLA identical
donors, mostly including thiotepa. GVHD prophylaxis
consisted of CyA and methotrexate (day + 1, + 3, + 6,
+/− 11), combined with Thymoglobuline for UD
transplants.
Stem cell sources and donors
In case of haploidentical transplantation, potential do-
nors were typed at the HLA-A, HLA-B, HLA-C, HLA-
DRB1, and HLA-DQB1 at a high resolution level. All the
donor/recipient pairs exhibited a median of 4 mis-
matches (range 2–5) on the unshared haplotype. The
donors underwent bone marrow harvest under general
anesthesia, and the target dose was 4 × 108 nuclear cells/
kg of recipient weight. In Marseille, 20 donors under-
went BM harvest, while 23 were mobilized by the sub-
cutaneous administration of G-CSF (5 to 6 days at
10 μg/kg/day). The target yield was 4 × 106 CD34/kg.
Unmanipulated stem cells were infused on day 0.
Supportive care
Each center applied specific supportive care in terms of
antimicrobial prophylaxis and transfusion policies.
Statistical analysis
The aims of this study were to evaluate the impact of
donor and disease status on outcome of allo-HSCT in
HL patients.
Patients were compared with respect to the main clin-
ical pathological characteristics: gender, age, number of
previous lines of therapy, therapeutic program, disease
status at transplant, CMV, ATG and conditioning regi-
mens. Differences between groups were evaluated by
using the T-test for continuous distributions and the
Chi-square or the Fischer exact test for categorical
distributions.
Survival analysis was defined according to the EBMT
criteria. Progression free survival (PFS), relapse incidence
(RI), overall survival (OS) and non-relapse mortality
(NRM) were evaluated starting time from allogeneic
transplantation. Cumulative incidence was considered to
estimate aGVHD, cGVHD, relapse incidence (RI) and
non-relapse mortality (NRM) after haploidentical trans-
plantation. Survival curves were generated by using
Kaplan-Meier method and differences between groups
were compared by the log rank test or by the log rank
test for trend when appropriated. To test whether the
differences in cumulative incidence were statistically sig-
nificant the Gray’s method was applied. All analysis were
performed using Stata 13 and R 3.0.3 softwares.
Results
Patient and transplantation characteristics are reported
in Table 1. The median time of observation for surviving
patients was 29months (range 14.1–57.4), with no dif-
ference between haplo and HLAid.
Engraftment
In the HAPLO group, the median time to reach an ANC
of more than 0.5 × 10^9/L, was 20 days (range 14–32),
and in the HLAid group 14 days (range 7–47). Failure to
engraft was seen in 3 HAPLO patients (7%) and in 2 pa-
tients (6%) in the HLAid group. In the haplo group, 2
out 3 patients had graft failure because of donor specific
antibodies (DSA), and 1 patient died of pneumonia be-
fore engraftment.
Acute and chronic GVHD
In the HAPLO and HLA-id group, the incidence of
grade 2–4 acute GVHD was 15% vs 16% (p = 0.9) and
chronic GVHD were 18% vs 32% (p = 0.06), respectively.
Survival, relapse and NRM (Table 2)
The overall 2-year PFS, OS, relapse incidence (RI), and
1y-NRM were 45, 66, 38, and 14%, respectively. The
PFS, OS, and RI were significantly better in patients in
CR compared to those in PR (55% vs 29% p = 0.001, 74%
vs 55% p = 0.03, 27% vs 55% p < 0.001, respectively.
(Figs. 1a, b, 2a), whereas the 1-year NRM was similar
(15% vs 16% p = 0.9).
The 2-year PFS for HAPLO and HLA-id HSCT, was
63% vs 37% (p = 0.03) (Fig. 1c), the 2-year OS 67% vs
63% (p = 0.6) (Fig. 1d), and the 1-year NRM was 13% vs
15%, (p = 0.9), respectively. The 2-year RI was signifi-
cantly lower in the HAPLO group (24% vs 44%, p =
0.008) (Fig. 2b).
We analyzed the clinical outcome in specific sub-
groups of patients, combining disease status and donor.
As shown in Table 2, patients in CR receiving a haplo
HSCT showed a significantly better 2-year PFS (Fig. 1e)
and lower 2-year RI (Fig. 2c) compared to those allo-
grafted with HLA-id donor (75% vs 47%, p < 0.001 and
11% vs 34%, p < 0.001, respectively). No statistically sig-
nificant differences were founded in terms of OS (Fig.
1g) and NRM. In PR patients, we found a similar advan-
tage for HAPLO donors with a 2-year PFS of 44% vs
22%, p < 0.001 (Fig. 1e); and the 2-year RI was 44% vs
60%, p < 0.001 (Fig. 2c). Finally, patients in PR receiving
transplantation from a HLAid donor showed the worst
outcome in terms of PFS and RI (22 and 60%, respect-
ively) (Figs. 1e and 2c).
Univariate and multivariate analysis (Table 3)
In univariate analysis, age (with a cut off at 45 years), re-
cipient CMV serostatus, ATG, conditioning regimen,
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therapeutic program (relapse post-HDC), and disease
status (CR vs PR) did not affect survival. Donor type
(HAPLO vs HLA-id) influenced the PFS (p = 0.06), but
not the OS. In multivariate analysis, donor type (haplo
vs HLA-id HR 0.51, p < 0.001) and disease status before
transplantation (CR vs PR HR 0.37, p = 0.014) were inde-
pendent predictors of PFS as well as they predict the risk
of relapse (donor type HR 0.37, p < 0.001; disease status,
HR 0.43, p = 0.006). Disease status at transplantation and
age (as continuous variable) were independently associ-
ated to OS (CR vs PR HR 0.57, p = 0.02; age HR 0.04,
p = 0.006).
Discussion
In this study, we have tested the effect of donor type on
outcome, in chemosensitive HL patients, undergoing an
allogeneic transplant from haploidentical donor, using a
Table 2 Main outcomes in all patients and specific sub-groups
N 2y PFS p 2y OS p 2y RI p 1y NRM p
All 18 45% 66% 38% 14%
CR vs PR 119 vs 79 55% vs 29% 0.001 74% vs 55% 0.03 27% vs 55% < 0.001 13% vs 16% 0.8
Haplo vs HLAid 65 vs 133 63% vs 37% 0.03 67% vs 63% 0.6 24% vs 44% 0.008 13% vs 15% 0.9
CR Haplo vs 37 75% < 0.001a 83% 0.1 6% < 14% 0.8
CR HLAid vs 82 47% 67% 34% 0.001a 13%
PR Haplo vs 28 44% 58% 44% 11%
PR HLAid 51 22% 54% 60% 18%
CR complete remission, PR partial remission, PFS progression free survival, OS overall survival, RI relapse incidence
atrend








Age, years (median, range) 32 (18–66) 32 (18–65) 31 (18–65) 0.8
Sex M/F 113/85 77/56 36/29 0.7
Number of CT lines (median, range) 2 (2–12) 2 (2–9) 4 (2–12) < 0.001
Previous HDC 170/198 (86%) 110/133 (83%) 60/65 (92%) 0.007
Disease status at transplantation
CR 119 (60%) 82 (62%) 37 (60%)
PR 79 (40%) 51 (38%) 28 (40%)
Donors NA
HLA sibling / 57 (43%) /
MUD / 76 (57%) /
Haplo / / 65
Stem cell source
PBSC 134 (60%) 114 (83%) 20 (31%) < 0.001
BM 63 (31%) 18 (13%) 45 (69%)
miss 1 (9%) 1 (4%) /
ATG prophylaxis GVHD NA
No 122 (62%) 57 (43%) /
Yes 76 (38%) 76 (57%) /
Conditioning regimens
NMAC 58 (29%) 2 (2%) 58 (89%) < 0.001
RIC 101 (51%) 92 (69%) 7 (11%)
MAC 39 (20%) 39 (29%) /
CR complete remission, PR partial remission, MUD matched unrelated donor, BM bone marrow, PBSC peripheral blood stem cells, HDC high-dose chemotherapy
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Fig. 1 PFS by disease status (a), donor type (c), and combining disease status and donor type (e), OS by disease status (b), donor type (d), and
combining disease status and donor type (g)
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T-replete stem cell source and PT-Cy, or HLA identical
donors, which included matched siblings and matched
unrelated donors.
We have shown that, haplo-HSCT result in a signifi-
cantly superior 2-year PFS (63%), when compared to
HLA identical transplants (37%). This is due to a signifi-
cantly reduced risk of relapse in HAPLO patients: the 2-
year cumulative incidence of relapse was indeed 24% for
HAPLO and 44% for HLA identical grafts. This was seen
despite the fact that HAPLO patients were all prepared
with a non myeloablative, extremely mild conditioning
regimen, whereas a proportion of patients in the HLA
identical cohort received a more intensive regimen, re-
cently shown to have a role in reducing tumor burden in
HL [14].
Remission status remained significant prognostic vari-
able in univariate and multivariate analysis, with CR pa-
tients having superior outcome as compared to partial
remission patients, in keeping with data in the literature.
When combining donor type and disease status, 37
HAPLO grafts in CR had the best 2 year PFS (75%), with
the lowest risk of relapse (6%). HLA identical grafts in
CR patients (n = 82) and HAPLO grafts in PR (n = 28)
had quite comparable outcome, with a PFS of 47 and
44%, and a risk of relapse of 34 and 44% respectively.
The worst outcome was in 51 patients in PR grafted
from HLA identical donors (22% PFS and 60% relapse).
This was confirmed in a multivariate analysis on PFS
and relapse, showing that donor type and remission sta-
tus were independent predictors.
Overall survival was predicted only by disease status
and patients age, but not by donor type: this is due to
the fact that non relapse mortality was similar in patients
grafted from HAPLO and HLA identical donors,
whereas is was influenced by disease status and age, In
addition post-transplant relapse can be rescued in HL
patients [15, 16], and therefore a strong effect on relapse
does not necessarily translate on survival, at least in the
short/medium term.
Another important point was the toxicity of haploi-
dentical transplantation: both in CR and PR groups, the
1-year NRM was low and not different as summarized in
Table 2. Similarly, the incidence of grade 2–4 aGVHD
was similar, despite the fact that 31% of HAPLO grafts
were performed using peripheral stem cells. Chronic
GVHD in the haplo group was in line with previous re-
ports, and basically lower compared to that observed in
HLAid group.
Fig. 2 Relapse incidence by disease status (a), donor type (b), and
both (c)
Table 3 Multivariate analysis
HR (CI95%) P value
PFS
Disease status (CR vs PR) 0.51 (0.34–0.75) < 0.001
Haplo vs HLAid 0.56 (0.35–0.89) 0.014
OS
Disease status (CR vs PR) 0.57 (0.35–0.93) 0.023
Age (continuous variable) 0.04 (1.00–1.05) 0.043
Relapse
Haplo vs HLAid 0.37 (0.23–0.60) < 0.001
Disease status (CR vs PR) 0.43 (0.43–0.79) 0.006
CR complete remission, PR partial remission, PFS progression free survival, OS
overall survival
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These results challenge those reported in other com-
parative studies from CIBMTR, including Hodgkin and
non-Hodgkin lymphomas, and one study from the
EBMT on HD patients only. The CIBMTR study com-
pared 44 patients grafted from haploidentical donors, to
178 patients transplanted from a matched related donor
[11]. They found no difference in terms of 3-year PFS
and RI (48% vs 48 and 37% vs 40%, respectively). In the
second CIBMTR study, haploidentical transplants were
compared to patients grafted from matched unrelated
donor. Again, no differences were observed in terms of
PFS and RI [12]. The recent EBMT study included HL
patients only and again the survival, NRM and aGVHD
incidence were similar between haplo-HSCT, matched
related donor and matched unrelated donor [13]. Other
studies from French Society of transplantation showed
similar results [14]. The question is why our present
study would instead show an advantage for HL patients
receiving a HAPLO graft: one possibility is the inclusion
criteria, since we enrolled exclusively patient with che-
mosensitive disease, whereas in the previous studies the
percentage of refractory patients was consistent (ranging
from 5 to 30%) [11–14]. Relapse rates are very high in
chemoresistant patients, also after an allogeneic trans-
plant, and this may quench the beneficial effect of given
donor type.
But why should HAPLO grafts have a stronger graft
versus HL effect? We hypothesize two possibilities. In
the first place donor lymphocytes may interact more
effectively with Hodgkin’s cellular microenvironment, in-
ducing apoptosis, and indirectly affecting survival of
Reed Sternberg cells [17]. The second possibility comes
from a recent study on check-point inhibitor activity
against HL: in this study, the activity of check-point in-
hibitors was higher when HL cells expressed HLA class
II molecules [18]. We speculate that class II HLA mis-
matches in a HAPLO transplant, may enhance the anti-
tumoral effect of donor CD4+ T cells.
The present study has several and important limitations,
mainly due to its retrospective nature, such that we cannot
exclude some bias in patient’s selection. The use of haploi-
dentical transplantation started in 2010, therefore patients
with an indication of HSCT and without a HLA-id donor
before that date did not undergo an allogeneic HSCT. In
addition, GvHD prophylaxis was different, based on PT-
CY in the HAPLO patients and on ATG in the HLA iden-
tical grafts, although in a previous analysis, ATG did not
significantly influence the outcome in lymphoma patients
receiving allogeneic stem cell transplantation [10]. Finally,
the conditioning regimen was the same for all HAPLO pa-
tients and rather heterogeneous in the HLA identical
group, although there is little evidence in the literature
that conditioning regimens influence the outcome of allo-
geneic HSCT in HL patients [19].
Conclusions
This study suggests that HLA haploidentical transplant-
ation, using T-cell replete stem cells and PT-Cy, is more
effective than HLA identical grafts in chemosensitive ad-
vanced HL, due to greater antitumor activity, challenging
the question of donor choice. A prospective comparative
study is needed, possibly using the same conditioning
regimen and the same prophylaxis for graft versus host
disease, in order to assess the role of HLA haploidentical
grafts for patients with Hodgkin lymphoma.
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